Pharmacist-Led Remote Diabetes Care Linked to Better Glycemic Control

This retrospective study suggests a structured, multimodal remote pharmacist service is associated with improved glycemic, cardiometabolic, and adherence outcomes in type 2 diabetes, though its non-randomized design precludes causal claims.

📅 Journal publication: 2026 (online Aug 4, 2026) · Last updated: Oct 7, 2026

clinical pharmacisttelepharmacyremote medication interventiontype 2 diabetes mellitusmedication adherenceHbA1cHOMA-IRSGLT2 inhibitorsGLP-1 receptor agonistsretrospective studymedication safetyhypoglycemia Endocrinology / Diabetes / Obesity

Also in Ambulatory Care / MTM, Clinical Practice

Background Information

Remote pharmacist-led interventions improve outcomes in type 2 diabetes mellitus.

Improving medication management in type 2 diabetes mellitus (T2DM) can enhance glycemic control and reduce complications. The intervention group showed significant improvements in glycemic indices (HbA1c, FPG, 2hPG), lipid profile, insulin resistance, medication adherence, and target attainment compared to controls. While promising, the study's non-randomized design limits causality claims and any single intervention component's effect cannot be isolated. Remote pharmacist-led interventions may enhance management of T2DM, improving outcomes and adherence.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Zhou Y, Liu X, Tang K, Cai Y, Yang Q, Wang B

Citation: Zhou Y, Liu X, Tang K, et al. Association between a clinical pharmacist-led multimodal remote medication intervention and individualized treatment outcomes in patients with type 2 diabetes mellitus. Frontiers in endocrinology. 2026;17:1867163. doi:10.3389/fendo.2026.1867163

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →